Latest Articles
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - Business Wire
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer Business Wire
Published: Oct. 27, 2025, 7:33 p.m.
Quanta Therapeutics Presents Positive Phase 1 Data for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, in Patients with Advanced Solid Tumors - The Manila Times
Quanta Therapeutics Presents Positive Phase 1 Data for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, in Patients with Advanced Solid Tumors The Manila Times
Published: Oct. 24, 2025, 3:57 p.m.
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - BioSpace
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer BioSpace
Published: Oct. 21, 2025, 5:15 a.m.
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - The AI Journal
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer The AI Journal
Published: Oct. 20, 2025, 9:33 p.m.
Faeth Therapeutics: $25 Million Raised To Advance PIKTOR Phase 2 Trial Following 80% Response Rate In Endometrial Cancer - Pulse 2.0
Faeth Therapeutics: $25 Million Raised To Advance PIKTOR Phase 2 Trial Following 80% Response Rate In Endometrial Cancer Pulse 2.0
Published: Oct. 20, 2025, 3:54 p.m.
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in E - PharmiWeb.com
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in E PharmiWeb.com
Published: Oct. 20, 2025, 3:02 p.m.
Faeth Therapeutics Raises $25 Million, Reports Phase 2 Results in Ovarian and Endometrial Cancer - Femtech Insider
Faeth Therapeutics Raises $25 Million, Reports Phase 2 Results in Ovarian and Endometrial Cancer Femtech Insider
Published: Oct. 20, 2025, 2:27 p.m.
Faeth Therapeutics’ $92 Million Total Funding Powers PIKTOR Phase 2 - citybiz
Faeth Therapeutics’ $92 Million Total Funding Powers PIKTOR Phase 2 citybiz
Published: Oct. 20, 2025, 1:40 p.m.
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - Business Wire
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer Business Wire
Published: Oct. 20, 2025, noon
Knight Therapeutics Announces Relaunch of MYFEMBREE® in Canada - GlobeNewswire
Knight Therapeutics Announces Relaunch of MYFEMBREE® in Canada GlobeNewswire
Published: Oct. 7, 2025, 9:08 p.m.
Link copied to clipboard!